Compare KLAR & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLAR | IMVT |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United Kingdom | United States |
| Employees | 2831 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.0B |
| IPO Year | N/A | 2019 |
| Metric | KLAR | IMVT |
|---|---|---|
| Price | $19.25 | $38.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $38.00 | $33.00 |
| AVG Volume (30 Days) | ★ 4.5M | 1.4M |
| Earning Date | 05-14-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.56 | N/A |
| Revenue Next Year | $19.93 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $14.32 |
| 52 Week High | $47.48 | $41.23 |
| Indicator | KLAR | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 58.46 |
| Support Level | $18.29 | $25.13 |
| Resistance Level | $22.09 | $41.23 |
| Average True Range (ATR) | 0.99 | 1.39 |
| MACD | -0.15 | -0.26 |
| Stochastic Oscillator | 25.26 | 37.50 |
Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.